Travere Therapeutics, Inc. Common Stock
TVTX
$47.76
+7.83%
Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney, liver, and metabolic diseases. The company is a specialized player in the orphan drug space, with its commercial and clinical prospects heavily tied to its lead investigational product, sparsentan, for rare kidney disorders. The current investor narrative is dominated by a pivotal catalyst, as evidenced by a dramatic 45% single-day stock price surge in mid-April 2026, which is almost certainly tied to a major binary event such as a positive regulatory decision or pivotal clinical trial readout for one of its key pipeline assets.…
TVTX
Travere Therapeutics, Inc. Common Stock
$47.76
Investment Opinion: Should I buy TVTX Today?
Rating & Thesis: Hold. The stock is a Hold due to its extreme binary risk/reward profile post-catalyst; the explosive 40% monthly gain has likely priced in near-term optimism, leaving limited immediate upside but significant downside if execution falters. The investment is now a bet on flawless commercial execution to justify the forward P/E of 9.05x.
Supporting Evidence: The valuation is stretched on a sales basis (PS 6.95x, EV/Sales 7.93x) but appears reasonable on forward earnings (P/E 9.05x), contingent on hitting the $5.15 EPS estimate. The 85.5% gross margin supports future profitability, but current fundamentals are weak with a -10.2% net margin and -43.8% ROE. The stock's technical position at 99% of its 52-week high suggests momentum is extended, and the wide analyst estimate dispersion (EPS range $4.28-$6.52) quantifies the high uncertainty.
Risks & Conditions: The two biggest risks are commercial execution failure for sparsentan and valuation compression from current elevated levels. This Hold would upgrade to a Buy if the stock consolidates and pulls back to stronger technical support near $30-$32, providing a better risk/reward entry, or if early launch metrics exceed the high end of revenue estimates. It would downgrade to a Sell if quarterly results show revenue significantly trailing the $1.59B average estimate or if the forward P/E multiple expands unjustifiably beyond 12x. The stock is currently fairly valued to slightly overvalued relative to its own risk-adjusted prospects, but not egregiously so if the bullish EPS scenario materializes.
Sign up to view all
TVTX 12-Month Price Forecast
The outlook is balanced with a neutral stance. The recent catalytic repricing has likely captured the near-term opportunity, shifting the investment case from event-driven speculation to execution-driven growth. The base case (50% probability) sees the stock trading sideways to slightly up as it proves out the $5.15 EPS estimate. The bull case requires flawless execution to drive further upside, while the bear case risks a sharp pullback to the $27-$29 support zone on any stumble. Confidence is medium due to the limited analyst coverage (4 analysts) and the binary nature of the remaining risks. The stance would upgrade to bullish on confirmation of revenue accelerating toward the high estimate, or downgrade to bearish on evidence of commercial launch delays or margin pressure.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Travere Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $62.09 and implied upside of +30.0% versus the current price.
Average Target
$62.09
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$38 - $62
Analyst target range
Analyst coverage for Travere Therapeutics is limited, with only 4 analysts providing estimates, which is typical for a small to mid-cap biotechnology stock and can lead to higher volatility and less efficient price discovery. The available data shows consensus estimates for future performance, with an average EPS estimate of $5.15 and an average revenue estimate of approximately $1.59 billion, but specific consensus price targets, recommendation distributions, and target price ranges are not provided. The high and low estimates for both EPS and revenue reveal a wide range of outcomes, with the high EPS estimate at $6.52 and the low at $4.28, and revenue estimates spanning from $1.38 billion to $1.91 billion. This wide dispersion signals significant uncertainty among analysts regarding the company's future commercial execution and the ultimate market penetration of its key therapies, reflecting the binary risk-reward profile inherent in developmental-stage biopharma.
Bulls vs Bears: TVTX Investment Factors
The bull case, driven by a recent major catalyst and the anticipation of a sharp profitability inflection (forward P/E 9.05x), currently has stronger evidence as reflected in the explosive 112.5% annual price appreciation. However, the bear case presents formidable risks centered on extreme valuation following the surge, deep fundamental losses, and high financial leverage. The single most important tension in the investment debate is the market's high-confidence pricing of future earnings ($5.15 EPS estimate) against the significant execution risk and wide analyst forecast dispersion. The thesis hinges entirely on the successful commercialization of sparsentan meeting or exceeding these optimistic expectations.
Bullish
- Major Catalytic Event Re-rating: The stock surged 45% in a single day in mid-April 2026, a move attributed to a major binary event like a positive regulatory decision or pivotal trial readout. This has driven a 112.5% gain over the past year and propelled the stock to trade at 99% of its 52-week high, signaling a fundamental re-rating of the company's prospects.
- High-Growth Profitability Inflection Priced In: The forward P/E of 9.05x, based on an average EPS estimate of $5.15, implies the market is anticipating a sharp, near-term transition to significant profitability. The vast gap between the negative trailing P/E (-67.8x) and the positive forward P/E underscores high confidence in the commercial launch and earnings ramp of its lead asset.
- Exceptional Gross Margin Potential: A gross margin of 85.5% is exceptionally high, typical of innovative biopharma with strong pricing power for orphan drugs. This provides a clear path to robust profitability once revenue scales, supporting the forward earnings estimates that drive the current valuation.
- Strong Liquidity to Fund Operations: A current ratio of 2.74 indicates strong short-term liquidity, which is critical for a clinical-stage company to fund ongoing operations, commercial launches, and pipeline development without immediate dilution risk. This provides a financial runway to execute on its catalysts.
Bearish
- Extreme Valuation & Price Overextension: Trading at 99% of its 52-week high ($44.70) after a 40.4% one-month surge, the stock shows signs of being overextended. The trailing PS ratio of 6.95x and EV/Sales of 7.93x are likely at peak levels, leaving little room for error and high vulnerability to a sharp pullback on any negative news.
- Deeply Negative Profitability & High Leverage: The company is deeply unprofitable with a net margin of -10.2% and an ROE of -43.8%. A debt-to-equity ratio of 2.86 indicates significant financial leverage, which amplifies both risk and return, making the equity highly sensitive to operational setbacks or delays in commercialization.
- High Analyst Uncertainty on Execution: Analyst estimates show a wide dispersion, with EPS forecasts ranging from $4.28 to $6.52 and revenue from $1.38B to $1.91B. This reflects significant uncertainty regarding commercial execution, market penetration, and ultimate sales for its lead therapy, sparsentan, highlighting the binary risk.
- Single-Asset Concentration Risk: The investment thesis is overwhelmingly tied to the success of sparsentan for rare kidney diseases. The company's market cap of $3.4B and recent price surge are a bet on this single product's approval and launch, creating a non-diversified, high-risk profile typical of developmental biotech.
TVTX Technical Analysis
The stock is in a powerful, sustained uptrend, having gained 112.52% over the past year. With a current price of $44.12, it is trading at approximately 99% of its 52-week high of $44.70, indicating extreme momentum and positioning at the upper bounds of its recent trading range, which suggests either strong bullish conviction or potential overextension. Recent momentum has been explosive, with the stock surging 40.42% over the past month and 41.91% over the past three months, dramatically outpacing the S&P 500's returns of 9.98% and 4.14%, respectively, over the same periods; this sharp acceleration from the longer-term trend confirms a major, news-driven re-rating. Key technical support now lies at the pre-catalyst levels around the $27-$29 range, which was the consolidation zone in March 2026, while immediate resistance is the absolute 52-week high of $44.70. A decisive breakout above this level would signal a continuation of the new bullish regime, while a failure could lead to a pullback to test the newfound support. The stock's beta of 0.868 indicates it has historically been less volatile than the market, but the recent price action demonstrates event-driven volatility that far exceeds this historical measure, necessitating careful risk management.
Beta
1.14
1.14x market volatility
Max Drawdown
-34.6%
Largest decline past year
52-Week Range
$14-$49
Price range past year
Annual Return
+211.3%
Cumulative gain past year
| Period | TVTX Return | S&P 500 |
|---|---|---|
| 1m | +17.0% | +4.9% |
| 3m | +60.7% | +8.9% |
| 6m | +34.9% | +9.8% |
| 1y | +211.3% | +26.9% |
| ytd | +20.9% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TVTX Fundamental Analysis
Revenue trajectory analysis is not possible as specific quarterly revenue and growth rate data are not available in the provided dataset. The company's profitability is deeply negative, with a trailing net margin of -10.24% and an EPS of -$0.015, reflecting its clinical-stage biotech profile focused on heavy R&D investment. However, the gross margin of 85.51% is exceptionally high, which is typical for an innovative biopharma company and suggests strong pricing potential for its therapies if successfully commercialized. The balance sheet shows a leveraged but liquid position, with a debt-to-equity ratio of 2.86, indicating significant financial leverage that amplifies risk and return. The current ratio of 2.74 suggests strong short-term liquidity to fund operations. Return metrics are deeply negative, with an ROA of -6.55% and an ROE of -43.77%, which is expected for a pre-profitability company burning cash to advance its pipeline. The forward P/E of 9.05x, based on estimated EPS, implies the market is anticipating a sharp transition to profitability in the near future, which is the core of the current investment thesis.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TVTX Overvalued?
Given the company's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 6.95x, while the Enterprise Value-to-Sales (EV/Sales) is 7.93x. The forward P/E ratio of 9.05x is available and meaningful, indicating the market is pricing in a near-term inflection to profitability, with the vast gap between the negative trailing P/E and positive forward P/E underscoring high growth expectations for earnings. Peer comparison data for industry averages is not available in the provided dataset, preventing a quantified assessment of any sector premium or discount. The stock's valuation is likely being judged on a sum-of-the-parts or risk-adjusted NPV basis relative to the commercial potential of its pipeline, rather than standard sector multiples. Historical context for the stock's own valuation ratios is not available in the provided dataset. However, the stock price trading at 99% of its 52-week high suggests the market is currently pricing in highly optimistic expectations, likely at or near the top of its historical valuation range following the recent catalytic event.
PE
-133.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
164.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Travere's financials reveal a high-risk, pre-profitability profile. The company carries significant financial leverage with a debt-to-equity ratio of 2.86, which magnifies losses as seen in the deeply negative ROE of -43.8%. Operational risk is concentrated in the commercial execution of its lead asset, sparsentan, as analyst revenue estimates vary widely from $1.38B to $1.91B, indicating uncertainty about market adoption. The company is currently burning cash, with negative net income and an operating margin of -12.8%, making it dependent on the success of its pivotal product to achieve the profitability implied by its forward P/E.
Market & Competitive Risks: The primary market risk is valuation compression. The stock trades at 99% of its 52-week high following a 40% monthly surge, with a trailing PS of 6.95x, suggesting it is priced for perfection. Any disappointment in launch timelines, pricing, or market share could trigger a severe de-rating. Competitive risks include existing or new therapies for FSGS and IgAN that could limit sparsentan's commercial peak. While the stock's beta of 0.868 suggests lower historical market correlation, the recent event-driven volatility demonstrates it is subject to binary, company-specific news flow that can cause dramatic swings independent of the broader market.
Worst-Case Scenario: The worst-case scenario involves a material setback in the commercialization of sparsentan, such as slower-than-expected physician adoption, payer reimbursement challenges, or adverse safety signals post-approval. This could lead to revenue falling toward the low end of analyst estimates ($1.38B) and EPS missing the $4.28 low estimate, invalidating the forward P/E thesis. A reversion to a pre-catalyst valuation could see the stock fall back to its March 2026 consolidation zone around $27, representing a downside of approximately -39% from the current $44.12. A breach of that level could target the 52-week low of $13.88, a catastrophic -69% decline, though this is less probable barring complete clinical failure of the pipeline.
FAQ
The key risks are: 1) Commercial Execution Risk: The thesis depends entirely on the successful launch of sparsentan; revenue estimates vary widely from $1.38B to $1.91B, highlighting uncertainty. 2) Financial Risk: The company is unprofitable (net margin -10.2%) and carries high debt leverage (D/E 2.86), amplifying downside. 3) Valuation Risk: Trading at 99% of its 52-week high after a massive surge, the stock is vulnerable to a sharp correction if growth expectations are not met. 4) Pipeline Concentration Risk: Beyond sparsentan, the pipeline is early-stage, leaving the company exposed to single-asset failure.
The 12-month forecast is bifurcated based on commercial execution. The base case (50% probability) sees the stock trading between $40 and $48 as it executes in line with average analyst estimates ($5.15 EPS). The bull case (30% probability) targets $50-$60 if launch exceeds expectations (EPS ~$6.52). The bear case (20% probability) risks a drop to $27-$35 if launch disappoints, retesting pre-catalyst support. The most likely scenario is the base case, contingent on the company meeting its near-term revenue and profitability milestones without major setbacks.
TVTX's valuation sends mixed signals. On a trailing basis, with negative earnings (P/E -67.8x) and a PS ratio of 6.95x, it appears expensive. However, the forward P/E of 9.05x, based on estimated EPS of $5.15, suggests the market is pricing in a dramatic near-term profitability inflection and could be considered reasonable for a high-growth biotech. The key is that the stock is likely fairly valued to slightly overvalued relative to the high execution risk embedded in those forward estimates. The market is paying a premium for anticipated growth that has not yet materialized in the financials.
TVTX is a speculative buy only for risk-tolerant investors who have already done thorough due diligence. Following a 40% monthly surge to $44.12, the near-term risk/reward is less attractive, as the stock now trades at 99% of its 52-week high. The forward P/E of 9.05x offers upside if the company hits its $5.15 EPS estimate, but the wide dispersion in analyst forecasts (EPS range $4.28-$6.52) and high debt leverage (D/E 2.86) present substantial downside. It may be a good buy on a significant pullback to the $30-$35 range for those believing in the sparsentan launch story.
TVTX is primarily suitable for a medium- to long-term investment horizon (2-3 years minimum) to allow the commercial story for sparsentan to fully unfold and for the company to transition to sustained profitability. The stock's low beta of 0.868 is misleading; recent event-driven volatility suggests it is unsuitable for short-term trading unless actively speculating on binary news. The lack of a dividend and the current pre-profitability stage mean returns will be driven entirely by capital appreciation from commercial execution. Investors should be prepared for high volatility and commit to a holding period that spans several quarterly earnings reports to assess the launch trajectory.